Group items tagged

The purpose of this funding opportunity announcement (FOA) is to provide support for New Investigators from backgrounds nationally underrepresented in biomedical research to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Mental Health (NIMH) and the Office of Dietary Supplements (ODS). The scientific mission areas of the Institutes and Office are: NIDDK -diabetes, endocrinology, metabolism, digestive diseases, hepatology, obesity, nutrition, kidney, urology, or hematology; NIMH factors contributing to mental disorders, the trajectories of mental disorders, pre-emption and treatment of mental disorders, identify and improve interventions for mental illness; and ODS all types of research in which the primary emphasis is the investigation of dietary supplements and/or their ingredients.

The purpose of this Funding Opportunity Announcement is to invite applications that investigate the mechanisms mediating the interactions between sleep and diabetes-related metabolism using deep metabolic phenotyping approaches in healthy human populations and those with metabolic and/or sleep disorders.

The purpose of this Funding Opportunity Announcement is to invite applications that investigate the mechanisms mediating the interactions between sleep and diabetes-related metabolism using deep metabolic phenotyping approaches in healthy human populations and those with metabolic and/or sleep disorders.

This FOA has two components, A and B. Component A: To support a 5-year multi-center research network of innovative, non-health system-based, natural experiments approaches to alter the diabetogenic characteristics of US communities. Priority areas include population-level approaches to the promotion of healthy eating and active living by evaluating the impact of environmental and policy interventions on population-level risk factors for diabetes. Component B: To fund a Central Coordinating Center (CCC) to provide organizational, logistic and communication support to enhance the efficiency, productivity, and impact of the Natural Experiments research centers that are funded as part of Component A.

This FOA has two components, A and B. Component A: To support a 5-year multi-center research network of innovative, non-health system-based, natural experiments approaches to alter the diabetogenic characteristics of US communities. Priority areas include population-level approaches to the promotion of healthy eating and active living by evaluating the impact of environmental and policy interventions on population-level risk factors for diabetes. Component B: To fund a Central Coordinating Center (CCC) to provide organizational, logistic and communication support to enhance the efficiency, productivity, and impact of the Natural Experiments research centers that are funded as part of Component A.

This Funding Opportunity Announcement (FOA) invites a High Impact Research and Research Infrastructure Cooperative Agreement application (UC4) from the Program Director/Principal Investigator (PD/PI) of the Data Coordinating Center (DCC) that has been involved in study design and coordination, and data and biosample acquisition and management, since the inception of The Environmental Determinants of Diabetes in the Young (TEDDY) consortium, an ongoing epidemiological study.

This Funding Opportunity Announcement (FOA) invites one application from the Program Director/Principal Investigator (PD/PI) of the current Data Coordinating Center (DCC) for The Environmental Determinants of Diabetes in the Young (TEDDY) study, an ongoing epidemiological study. This DCC has been involved in study design and data and bio sample acquisition and management since the inception of the TEDDY Consortium. This FOA provides support for the TEDDY DCC to continue to follow TEDDY children and allows funding for collaborators to conduct studies on integration of various "omics" data and the measurement and analysis of viral antibodies using samples from TEDDY subjects.

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel methods, biomaterials and devices for type 1 diabetes (T1D) treatment.

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development of targeted mass spectrometric assays (e.g. Multiple Reaction Monitoring) for proteins and peptides of primary interest to the type 1 diabetes research community (e.g. glucagon, somatostatin, C-peptide, insulin). The proposed assays should be highly reproducible, easily transferable to other laboratories, easy to multiplex, and validated in human plasma or serum.

This Funding Opportunity Announcement is intended to foster the development of a diverse and highly trained workforce of endocrinologists to assume leadership roles related to the Nations biomedical and behavioral research efforts in the area of type 1 diabetes (T1D). T1D is an autoimmune disease that occurs in both children and adults. Therefore, the NIDDK will award physician scientist career development program (K12) grants to eligible institutions to provide a program to prepare adult and/or pediatric endocrinologists, selected by the institution, for careers in basic or clinical research related to T1D. This Funding Opportunity Announcement (FOA) allows appointment of Scholars (K12) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development. Scholars may also propose fundamental research or human subjects research that is not a clinical trial.

This Funding Opportunity Announcement (FOA) invites applications for studies of etiology and pathogenesis related to development of type 1 diabetes (T1D) and/or its complications. Studies must involve subjects enrolled and followed in clinical trials, long term follow-up, or observational studies. This opportunity is intended to fund collaborative projects that bring new expertise and innovative approaches to enhance the value of major ongoing clinical research projects.

This Funding Opportunity Announcement is intended to foster the development of a diverse and highly trained workforce of endocrinologists to assume leadership roles related to the Nation's biomedical and behavioral research efforts in the area of type 1 diabetes (T1D). T1D is an autoimmune disease that occurs in both children and adults. Therefore, the NIDDK will award physician scientist career development program (K12) grants to eligible institutions to provide a program to prepare adult and/or pediatric endocrinologists, selected by the institution, for careers in basic or clinical research related to T1D. This Funding Opportunity Announcement (FOA) allows appointment of Scholars (K12) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development. Scholars may also propose fundamental research or human subjects research that is not a clinical trial.

This Funding Opportunity Announcement (FOA) invites applications for studies of etiology and pathogenesis related to development of type 1 diabetes (T1D) and/or its complications. Studies must involve subjects enrolled and followed in clinical trials, long term follow-up, or observational studies. This opportunity is intended to fund collaborative projects that bring new expertise and innovative approaches to enhance the value of major ongoing clinical research projects.

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing research on the use of current and emerging technologies for monitoring of blood glucose levels to capture the relationship between blood glucose excursions, perception of wellbeing, and cognitive status in people with type 1 diabetes (T1D). This information will inform the design of more effective interventions that may improve patient reported outcomes (PROs), including quality of life measures, and validate glycemic measures that may serve as outcomes in clinical trials to improve glucose management in T1D.

This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that addresses high priority HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities are described in NOT-OD-15-137: NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding. This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that addresses high priority HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities are described in NOT-OD-15-137: NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding.

The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases, and hematology. Additional information concerning programmatic areas at NIDDK is available at www.niddk.nih.gov/research-funding/research-programs/Pages/default.aspx and applicants are strongly encouraged to discuss research priorities with the Scientific Contact.

This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushing's diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets or data, for which the primary goal is data analysis and not preparation/presentation of data.

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development of targeted mass spectrometric assays (e.g. Multiple Reaction Monitoring) for proteins and peptides of primary interest to the type 1 diabetes research community (e.g. glucagon, somatostatin, C-peptide, insulin, and Glycated CD59). The proposed assays should be highly reproducible, easily transferable to other laboratories, easy to multiplex, and validated in human plasma or serum.

This FOA will support research to test approaches in the healthcare setting to using Patient-Reported Outcomes (PROs) as tools to enhance patient-centered treatment and improve outcomes in individuals with type 1 diabetes.

Type 1 diabetes (T1D) results in part from the autoimmune-mediated dysfunction or destruction of insulin-producing pancreatic beta cells. This funding opportunity is for projects that seek to discover ways to change the course of the disease by directly establishing tolerance. Immune responses could be engineered for tolerance induction through the manipulation of antigens, cells, or cellular microenvironments. Collaborations between T1D experts and investigators from other fields, including (but not limited to) cancer immunology and biomaterials engineering, are especially encouraged.

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing research on the use of current and emerging technologies for monitoring of blood glucose levels to capture the relationship between blood glucose excursions, perception of wellbeing, and cognitive status in people with type 1 diabetes (T1D). This information will inform the design of more effective interventions that may improve patient reported outcomes (PROs), including quality of life measures, and validate glycemic measures that may serve as outcomes in clinical trials to improve glucose management in T1D.

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective cell replacement therapies for type 1 diabetes (T1D). The purpose is to support research leading to the development and testing of novel and supportive technologies for the improvement of cell replacement interventions using novel biomaterials and devices for T1D treatment.